Huma Announces Partnership with Eckuity Capital to Accelerate M&A and Acquires Aluna
A global partnership agreement with Eckuity Capital to develop next-generation technology infrastructure—built on strong regulatory foundations—for the acquisition and launch of digital solutions in healthcare and research; and
The acquisition of Aluna (also known as Knox Medical Diagnostics, Inc.), a leading U.S.-based company specializing in intelligent remote monitoring and management of respiratory diseases.Huma x Aluna: (Front row, L to R) Charvi Shetty CEO of Aluna with Dan Vahdat CEO of Huma.
Accelerating Growth Through M&ATo fuel its continued expansion, Huma is announcing partnership and investment with Eckuity Capital. This strategic collaboration with a leading healthcare growth equity firm will help provide the resources necessary to advance Huma's aggressive M&A strategy, with the goal of acquiring complementary companies to build a comprehensive digital ecosystem supporting health systems, pharmaceutical companies, CROs, and patients worldwide.
Youssef Sebban, Managing Partner at Eckuity Capital, said: 'We help Huma acquire companies that, on their own, may not fully realize their potential—but when integrated into Huma's cloud platform, become highly complementary and transformative. This synergy not only amplifies their impact on the healthcare ecosystem but also drives outsized value creation for investors and shareholders.'
Dan Vahdat, Founder and CEO of Huma, said: 'Today's announcements mark a new chapter for Huma as we strive to build the most impactful healthcare company in the world. By integrating Aluna's leading respiratory monitoring solutions into our platform and working to secure growth capital for further acquisitions, we are creating a complete ecosystem to deliver even greater value to health systems, life sciences, and—most importantly—patients around the world.'
Huma's award-winning, disease-agnostic cloud platform has earned major regulatory certifications, including FDA 510(k) Class II and EU MDR Class IIb status. It supports over 4,500 hospitals and clinics and engages more than 50 million individuals across 70+ countries. Huma plays a pivotal role in national healthcare initiatives across the U.S., U.K., Germany, Greece, and Saudi Arabia, partnering with leading health systems, pharmaceutical companies, and CROs to redefine healthcare delivery.
Strengthening Respiratory Health CapabilitiesWith the acquisition of Aluna, Huma significantly expands its reach in respiratory health, adding over 150 U.S.-based health systems and clinic networks to its growing global footprint. Based in San Francisco, Aluna is a market leader in respiratory patient monitoring and medical device manufacturing, including its proprietary spirometers.
As part of the integration, Aluna's solutions will be relaunched on the Huma Cloud Platform, further enhancing their capabilities. The Huma Cloud Platform enables seamless, code-free configuration and AI/ML integration across a wide range of disease areas. The upgrade will also elevate Aluna's product classification to FDA Class II, unlocking greater clinical value for both patients and providers. All existing Aluna customers will gain access to Huma's comprehensive portfolio of disease management programs—spanning asthma, COPD, sleep apnea, and related conditions—serving approximately 500,000 contracted lives across these areas.
This strategic move positions Huma to better serve the more than 25 million asthma patients and 15 million COPD patients in the United States alone, while reinforcing its leadership in chronic respiratory care on a global scale.
Charvi Shetty, CEO of Aluna, remarked: 'Joining forces with Huma offers a remarkable opportunity to amplify our impact and extend the reach of our AI-driven respiratory management platform to a wider patient base worldwide. We are excited about the prospect of integrating our technology into the Huma Cloud Platform, creating a truly holistic digital health solution that empowers both patients and healthcare professionals in the effective management of respiratory conditions.'
Vishal Jain, Managing Partner at Eckuity Capital, said: 'We believe Dan and Huma's leadership team brings the much-needed bold vision to develop one of the most meaningful healthcare companies of the 21st century. The AI-led transformation of care that we will witness over the next two decades needs a reliable, real-time, and responsive infrastructure that very few companies can offer globally, and Huma is one of the most capable companies that can deliver on this promise.'
Goodwin Proctor was exclusive legal advisor to Huma Therapeutics Limited on the Aluna transaction. Peak Technology Partners served as the exclusive financial advisor to Aluna on the transaction.
Ends
Media images are here.
About HumaHuma is a healthcare AI company that owns and operates leading digital health applications. Its portfolio powers health systems, pharmaceutical companies, and CROs across more than 70 countries, transforming healthcare delivery at scale. Huma's disease-agnostic cloud platform is designed for rapid, no-code configuration and AI/ML integration, and has been recognized with FDA 510(k) Class II, EU/MDR Class IIb, and other major regulatory certifications. These capabilities enable the company to quickly launch new use cases and optimize acquired assets. Learn more at huma.com.
About Eckuity CapitalEckuity Capital is a global healthcare investment firm that supports high-growth companies at the inflection point in their growth cycle. The firm invests across Medtech, HealthTech, and Biotech Services to make a meaningful difference to patients, providers, and payors. With offices in New York and London, the firm focuses on solutions that bring positive changes to productivity, efficacy, distribution, and efficiency across the healthcare ecosystem.
About AlunaAluna provides an AI-powered remote patient monitoring solution, integrating a portable, FDA-cleared spirometer, an intuitive mobile application, and a clinician portal. This integrated system enables live, real-world tracking of lung function and respiratory health. Developed by UC Berkeley Engineering graduates with firsthand experience of respiratory conditions, Aluna prioritizes user-friendliness and engagement, incorporating interactive features and rewards to encourage consistent use and adherence. Aluna's provider dashboard allows doctors to remotely access patient data, enhancing telemedicine capabilities and offering valuable health insights. The collection of real-time data in everyday settings allows for the assessment of respiratory medication and therapy effectiveness for individuals affected by asthma, COPD, cystic fibrosis, and other respiratory conditions.
CONTACT: For further information please contact the Huma press office: Bilal Mahmood on b.mahmood@stockwoodstrategy.com or +44 (0) 771 400 7257.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
10 hours ago
- CNBC
Ascent Funding Student Loans: 2025 Review
Paying for college often means turning to private student loans — and many of those require a cosigner, especially if you don't have an established credit history or steady income. A cosigner can help you qualify and even secure a lower interest rate. But not everyone has someone they can ask. Ascent Funding offers students the flexibility to apply with or without a cosigner, depending on their financial or academic profile. But it also offers flexible repayment plans, generous loan limits and cash back perks. 3.09% to 15.61% APR with autopay discount (undergraduate new loan). Other rates and loan types are available. Visit Ascent's website for full details. Undergraduate and graduate loans, MBA, medical school, dental school, law school, doctorate and Master's, health professional loans. $2,001 up to $200,000 for undergraduate loans and $400,000 for graduate loans 5, 7, 10, 12, 15, 20 years Deferment and forbearance options available For DACA recipients and non-U.S. citizens or permanent residents No Terms apply. Ascent offers private student loans for students attending eligible undergraduate or graduate programs. If you're a graduate student, you can also apply for a cosigned credit-based loan if you have a creditworthy cosigner, such as a parent, guardian or sponsor, or a non-cosigned credit-based loan if you meet certain credit and income requirements on your own. If you're enrolled in a specific type of graduate program, there are customized repayments terms available for: Ascent also offers parent student loans for parents, grandparents, guardians or sponsors who want to help cover education costs, though eligibility requirements apply, as well as bootcamp loans, which are consumer loans designed for career-focused bootcamps or accelerated-learning programs. Offers in this section are from affiliate partners and selected based on a combination of engagement, product relevance, compensation, and consistent and graduate students, parents, health professionals$5,000 minimum (or up to state); maximum up to cost of attendance5, 7, 10, 15, years; up to 20 years for refinancing loans Terms applyUndergraduate and graduate students, parents, international students with U.S. co-signer$1,000 up to the cost of attendance ($180,000 lifelong maximum)5, 8, 10, 15 years for undergraduate loans, up to 20 years for graduate loans Terms apply To qualify for an Ascent student loan, you must be enrolled at least half-time at an eligible institution. If you're applying for a non-cosigned outcomes-based loan, you must be a junior or senior enrolled full-time, or half-time within nine months of graduation at an eligible school. If you're applying with a cosigner, your cosigner must have a minimum gross annual income of $24,000 for both the current and previous year. For the outcomes-based loan, you'll need to maintain a minimum GPA of 3.0 and meet your school's satisfactory academic progress standards. Borrowers must be at least half-time in a degree program at an eligible U.S. college or university Ascent doesn't publicly disclose specific credit score requirements but approval depends on several factors, including: You can use Ascent's prequalification tool to get a better sense of which loan options you may be eligible for, without impacting your credit score. The exact rates and terms of your Ascent loan may vary based on your credit and program. Ascent offers fixed rates starting as low as 3.09% APR and variable rates starting at 4.31% APR. Ascent offers loan terms of 5, 7, 10, 12, 15 or 20 years. There's no prepayment penalty so you can pay off your loan early without added fees. If you select a 20-year term, you'll only be eligible for variable interest rates. And for loans with low balances, your minimum monthly payment account may shorten the total repayment period — meaning your loan may be paid off faster than the selected term. Ascent does not charge any application, disbursement, prepayment or late fees. The minimum loan amount available to borrowers is $2,001, while in Massachusetts it's $6,001. The maximum is $200,000 for undergraduate students, and $400,000 for graduate students. Ascent offers a variety of repayment options based on your credit profile and whether you apply with or without a cosigner. Interest-only: Pay only the interest while in school and during the grace period. Full payments begin after graduation. $25 minimum: Make flat $25 monthly payments while in school. Full payments start after graduation. Deferred: Make no payments while in school. Interest accrues and is added to the loan balance when repayment begins. Other than not always needing a cosigner, Ascent offers a range of perks. 1% cash back reward: You can get 1% of your original loan amount back when you graduate, as long as you meet certain eligibility requirements. Up to 1% interest rate discount: You can sign up for automatic payments to receive an interest rate reduction (0.25% for autopay, with additional promotional offers sometimes available). High loan limits: You can borrow up to $200,000 for undergraduate loans, and up to $400,000 for graduate loans. Ascent offers several advantages but there are some limitations to consider. Ascent offers support via phone, email and live chat during business hours. It's generally well-rated for ease of application but customer service experiences can vary. Applying for a student loan with Ascent is generally straightforward: While Ascent offers flexible borrowing options, its interest rates can fall on the higher side, especially if you don't qualify for discounts. If low rates are your priority, Earnest offers some of the lowest starting APRs among private lenders. It also lets you pick your exact repayment timeline and doesn't charge late fees. Undergraduate and graduate students, parents, half-time students, international and DACA students Undergraduate, graduate loans, parent loans, MBA, medical school, law school, international and DACA student loans $1,000 up to the cost of attendance for new loans, $5,000 to $550,000 for refinance loans 5, 7, 10, 12, 15 years Nine-month grace period available No Yes - click here for details Terms you're looking to refinance your student loans after graduation, SoFi is a top alternative. SoFi allows you to consolidate federal and private loans with no fees and potentially lower your interest rate, especially if your credit has improved or your income has increased. 3.23% to 15.99% APR with 0.25% autopay discount (Undergraduate New Loan). Other rates and loan types are available. Visit SoFi's website for full details. Undergraduate, graduate, parent loans, law school, MBA and health professions loans $5,000 (or state-mandated minimum) up to the cost of attendance 5, 7, 10, 15 years; refinancing loans up to 20 years No Yes - click here for details Yes - click here for details Terms matters — so make the most of it. Get expert tips, strategies, news and everything else you need to maximize your money, right to your inbox. Sign up here. At CNBC Select, our mission is to provide our readers with high-quality service journalism and comprehensive consumer advice so they can make informed decisions with their money. Every student loan review is based on rigorous reporting by our team of expert writers and editors with extensive knowledge of student loan products. While CNBC Select earns a commission from affiliate partners on many offers and links, we create all our content without input from our commercial team or any outside third parties, and we pride ourselves on our journalistic standards and ethics.
Yahoo
12 hours ago
- Yahoo
Truist Lowers PT on Mastercard Incorporated (MA) from $640 to $612; Maintains ‘Buy' Rating
Mastercard Incorporated (NYSE:MA) secures a place on our list of the . Pixabay/Public Domain Ahead of its Q2 earnings, Truist decreased its price target on Mastercard Incorporated (NYSE:MA) from $640 to $612, maintaining a 'Buy' rating, reflecting its continued confidence in the stock. While the Fintech sector has lagged behind the broader market's 6% gain with just a 2% gain in 2025, the analyst anticipates growth ahead. Stablecoins and crypto are gaining investor attention, and they will be discussed in the upcoming earnings calls, according to the analyst. With these discussions, companies are expected to explain how these digital assets could impact the payments landscape. While the short-term outlook may seem shaky for Mastercard Incorporated (NYSE:MA), emerging innovations in the sector continue to attract investor interest. Mastercard Incorporated (NYSE:MA), based in the U.S., offers transaction processing and other related products and services. It is one of the best ESG stocks. While we acknowledge the potential of MA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and 11 Best Mineral Stocks to Buy According to Hedge Funds. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Hamilton Spectator
16 hours ago
- Hamilton Spectator
As Trump's trade deal deadline approaches, his tariffs face legal pushback in court
WASHINGTON - Donald Trump's plan to realign global trade faces its latest legal barrier this week in a federal appeals court — and Canada is bracing for the U.S. president to follow through on his threat to impose higher tariffs. While Trump set an Aug. 1 deadline for countries to make trade deals with the United States, the president's ultimatum has so far resulted in only a handful of frameworks for trade agreements. Deals have been announced for Japan, Vietnam, Indonesia, the Philippines and the United Kingdom — but Trump indicated last week that an agreement with Canada is far from complete. 'We don't have a deal with Canada, we haven't been focused on it,' Trump told reporters Friday. Trump sent a letter to Prime Minister Mark Carney threatening to impose 35 per cent tariffs if Canada doesn't make a trade deal by the deadline. The White House has said those duties would not apply to goods compliant with the Canada-U.S.-Mexico Agreement on trade. Canadian officials have also downplayed expectations of a new economic and security agreement materializing by Friday. 'We'll use all the time that's necessary,' Carney said last week. Countries around the world will also be watching as Trump's use of a national security statute to hit nations with tariffs faces scrutiny in the United States Court of Appeals for the Federal Circuit. The U.S. Court of International Trade ruled in May that Trump does not have the authority to wield tariffs on nearly every country through the use of the International Economic Emergency Powers Act of 1977. The act, usually referred to by the acronym IEEPA, gives the U.S. president authority to control economic transactions after declaring an emergency. No previous president had ever used it for tariffs and the U.S. Constitution gives power over taxes and tariffs to Congress. The Trump administration quickly appealed the lower court's ruling on the so-called 'Liberation Day' and fentanyl-related tariffs and arguments are set to be heard in the appeal court on Thursday. The hearing combines two different cases that were pushing against Trump's tariffs. One involves five American small businesses arguing specifically against Trump's worldwide tariffs, and the other came from 12 states pushing back on both the 'Liberation Day' duties and the fentanyl-related tariffs. George Mason University law professor Ilya Somin called Trump's tariff actions a 'massive power grab.' Somin, along with the Liberty Justice Center, is representing the American small businesses. 'We are hopeful — we can't know for sure obviously — we are hopeful that we will continue to prevail in court,' Somin said. Somin said they are arguing that IEEPA does not 'give the president the power to impose any tariff he wants, on any nation, for any reason, for as long as he wants, whenever he feels like it.' He added that 'the law also says there must be an emergency and an unusual and extraordinary threat to American security or the economy' — and neither the flow of fentanyl from Canada nor a trade deficit meet that definition. U.S. government data shows a minuscule volume of fentanyl is seized at the northern border. The White House has said the Trump administration is legally using powers granted to the executive branch by the Constitution and Congress to address America's 'national emergencies of persistent goods trade deficits and drug trafficking.' There have been 18 amicus briefs — a legal submission from a group that's not party to the action — filed in support of the small businesses and states pushing against Trump's tariffs. Two were filed in support of the Trump administration's actions. Brent Skorup, a legal fellow at the Washington-based Cato Institute, said the Trump administration is taking a vague statute and claiming powers never deployed by a president before. The Cato Institute submitted a brief that argued 'the Constitution specifies that Congress has the power to set tariffs and duties.' Skorup said there are serious issues with the Trump administration's interpretation of IEEPA. 'We don't want power consolidated into a single king or president,' he said. It's expected the appeals court will expedite its ruling. Even if it rules against the duties, however, they may not be immediately lifted. White House Press Secretary Karoline Leavitt has said the Supreme Court should 'put an end to this.' There are at least eight lawsuits challenging the tariffs. Canada is also being hit with tariffs on steel, aluminum and automobiles. Trump used different powers under the Trade Expansion Act of 1962 to enact those duties. This report by The Canadian Press was first published July 27, 2025.
